Pharmaceutical Technology

MAY 31, 2023

Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Clinical Trials 100

Clinical Trials Clinical Trials Production Licensing 100

Pharmaceutical Technology

MARCH 4, 2023

Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It acts by targeting prostacyclin receptor.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 4, 2023

Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It acts by targeting prostacyclin receptor.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

pharmaphorum

NOVEMBER 9, 2021

On Wednesday 7 th December at 3pm GMT / 4pm CET / 10am EST , experts from Cerner Enviza will debate with industry leaders responsible for oncology’s most successful brands and those making the treatment choices for patients. How oncologists make connections to brands. The success of branding in immuno-oncology.

Branding 94

Branding Scientist Marketing Containment 94

Pharmaceutical Technology

FEBRUARY 27, 2023

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Drug Delivery 100

Drug Delivery Drug Delivery Systems Production Drugs 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

JULY 26, 2022

There are two branded miglustat therapies available across the 3MM, with the US market having Johnson and Johnson’s (J&J, US) Zavesca and also generic miglustat available, but neither of these are approved for the treatment of NPC, so physicians prescribe this therapy off-label.

Marketing 306

Marketing Gene Branding Sales 306

Drug Discovery World

AUGUST 30, 2022

The importance of brand stratefy & development in your commercialisation journey. Patient engagement during clinical development: keeping the “customer” in mind. Spotlight roundtables. Operational excellence within manufacturing: Commercalisation vs cost. Moderator: Joel Eichmann, Co-founder, Green Elephant Biotech.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

JANUARY 6, 2021

However, there was a pause in developments in this field after psychedelic research was banned in the late 1960s. Some include Mind Medicine, Compass Pathways and Champignon Brands. Due to the team’s experience, we have an extensive playbook to draw from to manage clinical trials even under the most trying of times.”

Drugs 97

Drugs Clinical Trials Clinical Trials Medicine 97

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. “Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Development 40

Development Bioavailability Production Drugs 40

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Sarclisa has been tipped to become a $1 billion-plus brand, but it still has a long way to go.

Trials 93

Trials Sales Drug Delivery Antibody 93

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Hormones 40

Hormones Trials Branding Development 40

pharmaphorum

SEPTEMBER 17, 2020

The UK big pharma hasn’t revealed how much it is paying for rights to the drug candidate, originally developed by US biotech Dogma Therapeutics, which is still in preclinical development. At the moment no oral PCSK9 drugs have started clinical development, and AZ says it intends to start clinical testing of Dogma’s candidate next year.

Drugs 60

Drugs Antibody Sales Branding 60

pharmaphorum

JANUARY 19, 2022

From clinical development to commercialization, cross?functional Fishawack Health has had the privilege of working on dozens of new drug launches in recent years as the Brand Agency of Record—working with many biotech and biopharma companies on their first commercial launch. tracked or receives priority review.

Production 52

Production Branding Sales Clinical Development 52

Cloudbyz

MAY 4, 2022

NAPERVILLE, Ill. , May 4, 2022 /PRNewswire/– Cloudbyz , a fast-growing integrated clinical research and development solution provider with integrated capabilities, today announced that it has partnered with Tech Mahindra to provide integrated Clinical Trial Management Solutions.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

XTalks

JUNE 14, 2023

“The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis”, said John D. Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

Intouch Solutions

FEBRUARY 23, 2023

A 2021 Accenture survey of 12,000 patients in six countries found that only 16% were aware of a patient service offered to them by a brand. DTC ads and patient creative may need to elevate a brand’s financial offerings. Agile brands are recutting existing TV spots to include information about copay cards or financial assistance.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

Intouch Solutions

FEBRUARY 23, 2023

A 2021 Accenture survey of 12,000 patients in six countries found that only 16% were aware of a patient service offered to them by a brand. DTC ads and patient creative may need to elevate a brand’s financial offerings. Agile brands are recutting existing TV spots to include information about copay cards or financial assistance.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. Alexion’s new development hub.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company NRG Therapeutics Ltd.,

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We In particular, AI bears vast potential for advancing radiology.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

MAY 31, 2023

Headquartered in California, Acelyrin is a late-stage clinical biopharmaceutical company dedicated to expediting the development and delivery of groundbreaking medicines in the field of immunology. Additionally, CytoMed Therapeutics has extended the CAR-T principle to develop innovative therapies for solid tumors. per share.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

pharmaphorum

JANUARY 28, 2022

Biogen will retain its commercial rights to the biosimilars already brought to market, as well as copycat version of Bayer’s age-related macular degeneration blockbuster Eylea (aflibercept) that is still in clinical development.

Sales 52

Sales Marketing Branding Production 52

The Pharma Data

FEBRUARY 13, 2022

Asundexian is an oral inhibitor of Factor XIa (FXIa) that Bayer is developing as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke as well as for two additional conditions: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack). billion euros.

Clinical Trials 40

Clinical Trials Clinical Trials Life Science Trials 40

pharmaphorum

SEPTEMBER 21, 2021

We need to ensure qualified patients are diagnosed, identified and engaged early on in drug development”. Fortunately, we are now experiencing significant progress in gene therapy and other platform approaches targeting rare diseases, with a number of them focused on devastating CNS conditions.

Gene Therapy 77

Gene Therapy Gene Clinical Trials Clinical Trials 77

pharmaphorum

SEPTEMBER 20, 2021

However, Byooviz – which also has mCNV and RVO on its US label – isn’t due to launch there until next year under the terms of a deal with Roche, which has US rights to the Lucentis brand and claims additional patent protection until 2022.

Drugs 72

Drugs Sales FDA Approval Marketing 72

The Pharma Data

JUNE 28, 2021

Bayer announced today that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has approved soluble guanylate cyclase (sGC) stimulator vericiguat under the brand name Verquvo. Vericiguat is being jointly developed with MSD (a tradename of Merck & Co., The vericiguat program is being co-developed by Bayer and MSD.

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. 1 Can this really be regarded as a success? Scientists can now draw upon a range of innovative technologies that use human cells.

Medicine 59

Medicine Genome Genomics Drugs 59

The Pharma Data

APRIL 4, 2022

Chief Medical Officer and Head of Global Product Development, Roche. COVACTA was conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services (HHS).

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials In-Vitro 52

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. With this funding now complete, the Company is excited about its prospects for 2021 – as it pertains to its pharmaceutical development efforts. . NEW YORK, NY, Dec. The Patent, filed with the U.S.P.T.O.

Life Science 52

Life Science Manufacturing Production Development 52

The Pharma Data

DECEMBER 13, 2020

Zai Labs obtained regional development and commercialization rights for the programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab is leading clinical development in its territory. “We That collaboration was to develop and commercialize four oncology antibody biosimilar therapies. Most Read Today.

Antibody 52

Antibody Clinical Trials Clinical Trials Licensing 52

Drug Discovery World

JUNE 5, 2023

New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company? How to improve its pipeline?

Genome 52

Genome Genomics Life Science Genetics 52

The Pharma Data

MARCH 23, 2021

Berlin, March 23, 2021 – Bayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi , for the treatment of Neurotrophic Tyrosine Receptor Kinase ( NTRK ) fusion-positive advanced or recurrent solid tumors. Fields, M.D.,

Genome 52

Genome Genomics Gene Protein 52

The Pharma Data

DECEMBER 28, 2020

in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine. ” Zidong Zhang said, “The biotech sector in Asia is still in its infancy and there will be significant growth in demand for quality clinical trial services as the sector develops.

Clinical Trials 40

Clinical Trials Clinical Trials Research Analyst Trials 40

The Pharma Data

MAY 31, 2022

Senior Vice President, Clinical Development, BlueRock Therapeutics. “We We are excited that our Phase 1 clinical trial has completed enrollment and believe it is a critical next step toward the development of a novel cell therapy that has the potential to transform the treatment landscape for this devastating disease.”.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52